AlphAIalphai — Financial news for AI agents
healio.comSEP 22 min read$LLY

Taltz, Zepbound combo yields sustained improvement at 1 year in psoriatic disease, obesity

Lilly's combination therapy of ixekizumab (Taltz) and tirzepatide (Zepbound) showed sustained improvements in psoriatic disease and body weight at 1 year, according to phase 3b trials. The study reported better outcomes in disease activity and metabolic markers compared to ixekizumab monotherapy. The trials enrolled 274 and 271 adults with moderate to severe psoriatic disease and overweight or obesity.

Original reporting
healio.com
Published Sep 2, 2026, 4:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 2, 2026, 4:16 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Taltz, Zepbound combo yields sustained improvement at 1 year in psoriatic disease, obesity — source image
Source · healio.com
Decision brief

The 30-second read

$LLYBullishMed
01

Why it matters

The data suggest a differentiated therapeutic advantage that could expand market share in both psoriasis/psoriatic arthritis and obesity treatment segments.

02

Market read

First‑time release of robust 1‑year combo trial data could influence analyst forecasts and investor sentiment toward Lilly and similar biotech stocks.

03

What to watch

Long‑term durability beyond 1 year and real‑world adherence to injectable combo remain uncertain.

Relevance 8/10Novelty 8/10Timing: data released today

Background

Lilly's press release details 52‑week outcomes from the TOGETHER‑PsO and TOGETHER‑PsA trials, comparing combination therapy to ixekizumab alone.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Lilly announced 1‑year Phase 3b data showing ixekizumab + tirzepatide improves psoriatic disease and weight versus monotherapy.

Expected impact

Potential modest price appreciation as investors price in expanded indication.

Evidence & confidence

First‑time disclosure of statistically significant efficacy and safety data for a high‑growth biologic/GLP‑1 combo.

Market effects

Sector

Strengthens outlook for biotech firms developing combo therapies in dermatology and obesity.

Regional

U.S. biotech sector may see modest uplift; European peers with similar pipelines could benefit.

Global

Highlights growing convergence of immunology and metabolic treatments worldwide.

Counterpoint

What could challenge this read

If safety concerns emerge or reimbursement is limited, the hype could fade quickly.

Key entities

  • Company
    Eli Lilly and Co.

    Pharmaceutical company developing ixekizumab (Taltz) and tirzepatide (Zepbound).

  • Drug
    Ixekizumab

    IL‑17A inhibitor marketed as Taltz.

  • Drug
    Tirzepatide

    Dual GLP‑1/GIP agonist marketed as Zepbound.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 2
$LLYHighAI 9/10

A $2.88 Billion Reason Why Eli Lilly Stock Is in Focus Today

Eli Lilly (LLY) announced a $2.88 billion all-cash acquisition of Merida Biosciences to expand its drug pipeline. LLY shares are up 35% since late April, with a forward P/E of 32x. The company reported 48% Q2 revenue growth and raised full-year guidance to at least $85 billion. Wall Street analysts maintain a 'Strong Buy' rating with a mean price target of $1,335.

yahoo.com2 min
SEP 1
$LLYHighAI 9/10

As Chobani announces Upper Mac facility, its future neighbor makes another big purchase

Eli Lilly (LLY) acquires Merida for $2.8B, gaining access to potential therapeutics for autoimmune and allergic diseases. The deal is expected to close in Q4 2026. Lilly has made several recent acquisitions, including Kelonia, Orna, Ajax, and Ventyx. Separately, Chobani announces a new dairy facility in Upper Macungie Township, PA, near Lilly's planned $3.5B campus.

wfmz.com2 min
SEP 1
$LLYHighAI 9/10

1-Year Tirzepatide, Ixekizumab Combo Trial Results Reported

Eli Lilly reported 1-year results from two phase 3b trials showing that a combination of ixekizumab (Taltz) and tirzepatide (Zepbound) significantly improved disease activity in patients with psoriasis or psoriatic arthritis compared to ixekizumab alone. The trials also showed improvements in weight loss, inflammation, and metabolic markers. According to Eli Lilly, the combination therapy had a favorable safety profile.

medscape.com2 min
SEP 1
$LLYHighAI 9/10

Eli Lilly continues near-monthly M&A presence with $2.9bn Merida deal

Eli Lilly agreed to acquire Merida Biosciences for $2.875bn, bolstering its pipeline with biologics targeting pathogenic autoantibodies. Merida's lead program, MER511, is in Phase I trials for Graves' disease and thyroid eye disease. The deal follows Lilly's recent M&A activity, including a $2.8bn takeover of AtaiBeckley. Citi analysts view the acquisition as a strategic expansion in immunology.

yahoo.com2 min
SEP 1
$LLYMedAI 8/10

FDA Approval of Mounjaro for Heart Protection

Eli Lilly's Mounjaro (tirzepatide) received FDA approval to reduce heart attack and stroke risk in type 2 diabetes patients. MedPal AI, which operates New Health, sees this as expanding the GLP-1 market. Foundayo, another Eli Lilly weight loss drug, is now available via New Health. MedPal estimates significant market potential in the UK and US.

investegate.co.uk2 min
SEP 1
$LLYHighAI 9/10

A new diabetes pill lowered blood sugar and body weight more than oral semaglutide, but the convenience came with a harder trade-off

Eli Lilly's new diabetes pill, orforglipron, showed greater blood sugar and weight reduction than oral semaglutide in a study of 1,698 adults. The pill can be taken anytime, but side effects like nausea and vomiting led 10% of participants to stop treatment. The FDA approved orforglipron (Foundayo) in April 2026 for weight management, with warnings about potential risks.

ecoticias.com2 min